Donanemab in Early Alzheimer’s Disease: Greater Benefit in Lower Tau Burden (P2-12.011)

Aswathi Sajeendran; Jamir Pitton Rissardo; Omar Elmandouh; Ana Leticia Fornari Caprara

doi:10.1212/wnl.0000000000213161

June 9, 2026Neurology

Donanemab in Early Alzheimer’s Disease: Greater Benefit in Lower Tau Burden (P2-12.011)

View at Publisher

Ask AI

Bookmark

Share

Key Points

The aim is to assess the effect of donanemab on cognitive and functional outcomes in Alzheimer's disease patients based on their tau burden.
Randomized trial comparing donanemab to placebo.
Participants classified into low/medium and high tau burden groups.
Cognitive and functional outcomes measured.
Donanemab significantly improved cognitive outcomes in low/medium tau burden patients compared to placebo.
Functional outcomes showed greater benefits in patients with lower tau levels.
High tau burden patients did not experience significant benefits from donanemab.

Implication

Randomized trial evaluates cognitive and functional outcomes of donanemab in AD patients stratified by tau burden, highlighting differential effects.

Abstract

To evaluate the effect of donanemab compared to placebo on cognitive and functional outcomes in Alzheimer’s disease (AD) patients stratified by tau burden (low/medium [L/M] vs. high [H]).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Sajeendran et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf393faef96ed7f0560a9 https://doi.org/10.1212/wnl.0000000000213161

View at Publisher

Ask AI

Bookmark

Share

Donanemab in Early Alzheimer’s Disease: Greater Benefit in Lower Tau Burden (P2-12.011)

Key Points

Implication

Abstract

Discussion

Cite This Study

Donanemab in Early Alzheimer’s Disease: Greater Benefit in Lower Tau Burden (P2-12.011)

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading